MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC RHINOCONJUNCTIVITIS, SENSITIZED TO HOUSE DUST MITES.
Latest Information Update: 04 Dec 2018
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Bial
- 30 Nov 2018 Status changed from recruiting to discontinued.
- 21 Nov 2016 New trial record